CompletedPHASE1, PHASE2NCT03918499

IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer

Studying Cerebrotendinous xanthomatosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
City of Hope Medical Center
Principal Investigator
Joseph Chao
City of Hope Medical Center
Intervention
Cyclophosphamide(drug)
Enrollment
9 target
Eligibility
18 years · All sexes
Timeline
20192023

Study locations (3)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03918499 on ClinicalTrials.gov

Other trials for Cerebrotendinous xanthomatosis

Additional recruiting or active studies for the same condition.

See all trials for Cerebrotendinous xanthomatosis

← Back to all trials